Voyageur Pharmaceuticals Ltd. has appointed Virginia Alling as an independent director, subject to regulatory approval, marking another strategic addition to its board as the company prepares for U.S. market expansion. This appointment follows recent board enhancements with Wall Street veterans Jeffrey J. Kraws and Christopher A. Van Buren, collectively positioning the Canadian pharmaceutical developer for accelerated access to U.S. capital markets and strategic growth initiatives.
Ms. Alling brings over three decades of experience in corporate banking, capital markets, and strategic advisory for both privately held and publicly traded companies. As Senior Vice President & Managing Director at PNC Bank in East Brunswick, NJ, she manages a multi-billion-dollar portfolio of corporate clients in New Jersey and New York, with expertise spanning mergers and acquisitions, initial public offerings, employee stock ownership plans, leveraged finance, and revenue optimization. Her background includes guiding private equity-backed and multigenerational family-owned businesses through capital structure solutions, succession planning, and risk management. Previously, she held vice president roles at JPMorgan Chase and Wells Fargo, and she holds an MBA from the Raymond A. Mason School of Business at the College of William & Mary, along with FINRA Series 7 & 63 licenses as a Registered Investment Adviser.
Brent Willis, Voyageur's CEO, stated that Ms. Alling's track record in executing U.S. public offerings, revenue optimization, and cross-border financing complements the recent appointments of Mr. Kraws and Mr. Van Buren. He emphasized that her deep experience in M&A and capital markets will be instrumental in unlocking institutional U.S. investment, streamlining U.S. market entry, and ensuring robust governance as the company scales its innovative barium and iodine pipeline for North American healthcare providers. Her expertise in family-owned enterprises and strategic partnerships aligns with Voyageur's vision of sustainable growth and value creation for shareholders.
The board enhancements underscore Voyageur's commitment to assembling a high-calibre team with proven Wall Street acumen to facilitate U.S. market expansion. The collective experience of Ms. Alling, Mr. Kraws, and Mr. Van Buren in revenue generation, IPO execution, and regulatory compliance is expected to support Voyageur's commercialization efforts, including FDA approvals for its barium contrast products and scaling of its Oklahoma iodine operations. Voyageur, trading under the symbol VM on the TSX Venture Exchange, is developing barium and iodine Active Pharmaceutical Ingredients for high-performance, cost-effective imaging contrast agents, with a strategic focus on vertically integrating the barium and iodine contrast markets.
At the core of its operations, Voyageur owns a 100% interest in the Frances Creek barium sulphate project, which features a rare and exceptional grade mineral suitable for the pharmaceutical marketplace. The company believes this resource will replace current synthetic products with higher quality imaging alternatives. Voyageur's business plan involves partnering with third-party GMP pharmaceutical manufacturers in Canada to validate its products by regulatory agencies worldwide, with plans to transition into a high-margin domestic manufacturer of radiology drugs. For more information, visit https://voyageurpharmaceuticals.ca. The company's forward-looking statements involve risks and uncertainties, with details available in disclosure documents on the SEDAR+ website at https://www.sedarplus.ca.
